Passive Immunotherapy in the Treatment of Advanced Human Immunodeficiency Virus Infection

Journal of Infectious Diseases

Volumn 168, Issue 2, 1993, Pages 298-305

  Jacobson, Jeffrey M ^a,b   Colman, Neville ^a,b   Ostrow, Nancy A ^a,b   Simson, Robert W ^a,b   Tomesch, Donna ^a,b   Marlin, Laura ^a,b   Rao, Malia ^a,b   Mills, James L ^a,b   Clemens, John ^a,b   Prince, Alfred M ^a,b  

^a NEW YORK BLOOD CENTER   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; DIPHENHYDRAMINE; HYDROCORTISONE; HYPERIMMUNE GLOBULIN; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEVER; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SURVIVAL; THORAX PAIN; URTICARIA; VIREMIA; WHEEZING;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMAN; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTE COUNT; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; ZIDOVUDINE;

EID: 0027237524     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/168.2.298     Document Type: Article

References (39)

1. Salk J. The whole virus approach to immunization. In: Fauci AS. moderator. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection. Ann Intern Med 1989; 110: 378-81.
2. Weiss RA, Clapham PR, Cheingsons-Popov R, Neutralization of human T Iymphotropic virus type III by sera ofAIDS and AIDS-risk patients. Nature 1985: 316: 69-72.
3. Guroff M, Brown M, Gallo RC. HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985; 316: 72-4.
4. Karpas A, Gillson W, Bevan PC, Oates JO. Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies. Lancet 1985; 2: 695-7.
5. Weber IN, Clapham PR, Weiss RA. Human immunodeficiency virus infection in two cohorts of homosexual men: Neutralizing sera and association of anti-GAG antibody with prognosis. Lancet 1987; 1: 119-21.
6. Prince AM. Reesink H. Pascual D, Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991; 7: 971-3.
7. Emini EA. Nara PL. Schleif WA. Antibody-mediated in vitro neutralization of human immunodeficiency virus type I abolishes infectivity for chimpanzees. J Virol 1990; 64: 3674-8.
8. Putkonen P. Thorstensson R. Ghavamzadeh L. Prevention of HIV-2 and SIV8M infection by passive immunization in cynomolgus monkeys. Nature 1991; 352: 436-8.
9. Jackson GG. Perkins JT. Rubenis M. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet 1988; 2: 647-54.
10. Karpas A. Hill F. Youle M. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci USA 1988; 85: 9234-7.
11. Karpas A, Hewlett IK, Hill F. Polymerase chain reaction evidence for human immunodeficiency virus I neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci USA 1990; 87: 761-7.
12. Prince AM, Pascual D. Kosolapov LB. Kurokawa D, Baker L. Rubinstein P. Prevalence. clinical significance. and strain specificity ofneutralizingantibody to the human immunodeficiency virus. J Infect Dis 1987; 156: 268-72.
13. Holland PV, Bell CA, Boral LJ, Standards for blood banks and infusion services. 13th ed. Arlington. VA: American Association of Blood Banks, 1989: 14-5.
14. Karnofiky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; I: 634-56.
15. Prince AM. Horowitz B. Baker L. Failure of an HIV immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci USA 1988; 85: 6944-8.
16. SAS Institute. SAS/STAT user's guide. Version 6. 4th ed. Vol 2. Cary, NC: SAS Institute, 1989.
17. BMDP Statistical Software. BMDP statistical software manual. Vol 2. Los Angeles: BMDP Statistical Software. 1990.
18. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 8th ed. Oxford: Blackwell Scientific Publications. 1987: 25.
19. Jacobson MA, Besch CL, Child C, Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ 1991; 302: 73-8.
20. Fahey JF, Taylor JMG, Detels R. The prognostic value ofcellular and serologic markers in infection with human immunodeficiency virus type I. N Engl J Med 1990; 322: 166-72.
21. Anderson RE, Lang W. Shiboski S, Royce R. Jewell N, Winkelstein W. Use ofl32-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection. Arch Intern Med 1990; 150: 73-7.
22. Vittecoq D. Mattlinger B. Barre-Sinoussi F, Passive immunotherapy in AIDS: A randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis 1992; 165: 364-8.
23. Polk BF, Fox R, Brookmeyer R. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987; 316: 61-6.
24. Detels R, English PA, Giorgi JV. Patterns ofCD4+ cell changes after HIV-I infection indicate the existence of a codeterminant of AIDS. J Acquir Immune Defic Syndr 1988; I: 390-5.
25. Lang W. Perkins H. Anderson RE. Royce R. Jewell N. Winkelstein W. Patterns of T lymphocyte changes with human immunodeficiency virus infection: From seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989: 2: 63-9.
26. Brinchmann JE. Vartdal F. Thorsby E. T Lymphocyte subset changes in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1989; 2: 398-403.
27. Yarchoan R, Klecker RW, Weinhold KJ. Administration of 3'azido-3'-deoxythymidine, an inhibitor ofHTLV-III/LAV replication. to patients with AIDS or AIDS-related complex. Lancet 1986; I: 575-80.
28. Fischl MA, Richman DO, Grieco MH, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind. placebo-controlled trial. N Engl J Med 1987; 317: 185-91.
29. Feinstein AR. Clinical biostatistics XXIV. The other side of statistical significance: Alpha. beta. delta. and the calculation of sample size. Clin Pharmacol Ther 1975; 18: 491-516.
30. Berman PW. Groopman JE. Gregory T. Human immunodeficiency virus type I challenge ofchimpanzees immunized with recombinant envelope glycoprotein gp 120. Proc Natl Acad Sci USA 1988; 85: 5200-4.
31. Karwowska S. Zolla-Pazmer S. Passive immunization for the treatment and prevention of HIV infection. Biotechnol Ther 1991; 2: 31-48.
32. Rossi P, Moschese V, Broliden PA, Presence of maternal antibodies to human immunodeficiency virus I envelope glycoprotein gp 120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci USA 1989; 86: 8055-8.
33. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A. Vertical transmission ofhuman immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp 120 principal neutralizing domain. Proc Natl Acad Sci USA 1990; 87: 3445-9.
34. Takeda A, Tuazon CU, Ennis FA. Antibody-enhanced infection by HIV-I via Fe receptor-mediated entry. Science 1988; 242: 580-3.
35. Robinson WE, Montefiori DC, Gillespie DH, Mitchell WM. Complement mediated. antibody dependent enhancement of HIV-I infection in vitro is characterized by increased protein and RNA synthesis and infectious virus release. J Acquir Immune Defic Syndr 1989; 2: 33-42.
36. Tyler OS, Lyerly HK, Weinhold KJ. Anti-HIV-I ADCC, AIDS Res Hum Retroviruses 1989; 5: 557-63.
37. Bonavida B, Katz J, Gottlieb M. Mechanism ofdefective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells. and partial restoration by IL 2. J Immunol 1986; 137: 1157-63.
38. Hoffenbach A, Langlade-Demoyen P, Dadaglio G. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989; 142: 452-62.
39. Redfield RR, Birx DL, Ketter N. A phase I evaluation ofthe safety and immunogenicity of vaccination with recombinant gp I60 in patients with early human immunodeficiency virus infection. N Engl J Med 1991; 324: 1677-84.